NIH Locks Doors for Secret Allergy Grant Huddle
Published Date: 4/11/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on May 13-14, 2025, to review grant applications for small businesses working on anti-infective and immune disease treatments. This private meeting protects sensitive info like trade secrets and personal details. Small businesses aiming for funding should keep an eye on this important review process happening soon.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Small-Business Grant Reviews Scheduled
If you are a small business working on anti-infective or immune-disease therapeutics, NIH will review and evaluate grant applications in a closed meeting on May 13-14, 2025 (10:00 a.m. to 6:00 p.m.). The meeting is video assisted and will be held at 5601 Fishers Lane, Rockville, MD.
Confidentiality Protects Applicants' Trade Secrets
The meeting will be closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, patentable material, commercial property, and personal information of individuals associated with grant applications.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14980, Government Owned Invention Available for License: Pigment Epithelium-Derived Factor Peptides and Their Use for Treating Retinal Degeneration
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Previous / Next Documents
Previous: 2025-06173, Self-Regulatory Organizations; Financial Industry Regulatory Authority, Inc.; Notice of Filing of a Proposed Rule Change To Adopt FINRA Rule 6152 (Disclosure of Order Execution Information for NMS Stocks)
FINRA wants brokers to share more info about how they handle stock orders for popular U.S. stocks (NMS stocks). Starting soon, brokers will have to send their order execution data to FINRA, which will post it online for everyone to see. This change helps investors understand how well brokers are doing and could impact how trades are done, but no new fees are mentioned.
Next: 2025-06175, National Institute of General Medical Sciences; Notice of Closed Meeting
The National Institute of General Medical Sciences is holding a private virtual meeting from April 25-28, 2025, to review special grant applications for small businesses. This closed meeting protects sensitive info like trade secrets and personal details. It affects researchers and companies seeking funding, with no direct cost changes but important decisions on who gets grants.